Literature DB >> 24590584

Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists.

D M Berney1, F Algaba, P Camparo, E Compérat, D Griffiths, G Kristiansen, A Lopez-Beltran, R Montironi, M Varma, L Egevad.   

Abstract

It is not known how uropathologists currently report histopathological features of prostate biopsies such as core length, tumor extent, perineural invasion, and non-tumor-associated features such as inflammation and hyperplasia in needle biopsies. A web-based survey was distributed among 661 members of the European Network of Uropathology. Complete replies were received from 266 pathologists in 22 European countries. Total core lengths were reported by 64 %. The numbers of cores positive for cancer was given by 79 %. Linear cancer extent was reported by 81 %, most often given in millimeters for each core (53 %) followed by the estimation of percentage of cancer in each core (40 %). A gap of benign tissue between separate cancer foci in a single core would always be subtracted by 48 % and by 63 % if cancer foci were minute and widely separated. Perineural invasion was reported by 97 %. Fat invasion by tumor was interpreted as extraprostatic extension by 81 %. Chronic and active/acute inflammation was always reported by 32 and 56 % but only if pronounced by 54 and 39 %, respectively. While most (79 %) would never diagnose benign prostatic hyperplasia on needle biopsy, 21 % would attempt to make this diagnosis. Reporting practices for prostate biopsies are variable among European pathologists. The great variation in some methodologies used suggests a need for further international consensus, in order for retrospective data to be comparable between different institutions.

Entities:  

Mesh:

Year:  2014        PMID: 24590584     DOI: 10.1007/s00428-014-1554-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  32 in total

Review 1.  Role of histopathology and molecular markers in the active surveillance of prostate cancer.

Authors:  Rodolfo Montironi; Lars Egevad; Anders Bjartell; Daniel M Berney
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

2.  Perineural invasion on prostate biopsy does not predict adverse pathological outcome.

Authors:  Malik Elharram; David Margel; Antonio Finelli; John Trachtenberg; Andrew Evans; Theodorus H van der Kwast; Joan M Sweet; Neil Fleshner
Journal:  Can J Urol       Date:  2012-12       Impact factor: 1.344

3.  Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study.

Authors:  Edward W J Rowe; Marc E Laniado; Marjorie M Walker; Patel Anup
Journal:  BJU Int       Date:  2006-05       Impact factor: 5.588

4.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

5.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

6.  Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer.

Authors:  V Ravery; C Chastang; M Toublanc; L Boccon-Gibod; V Delmas; L Boccon-Gibod
Journal:  Eur Urol       Date:  2000-04       Impact factor: 20.096

7.  A multi-institutional evaluation of active surveillance for low risk prostate cancer.

Authors:  Scott E Eggener; Alex Mueller; Ryan K Berglund; Raj Ayyathurai; Cindy Soloway; Mark S Soloway; Robert Abouassaly; Eric A Klein; Steven J Jones; Chris Zappavigna; Larry Goldenberg; Peter T Scardino; James A Eastham; Bertrand Guillonneau
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

8.  Prediction of capsular perforation and seminal vesicle invasion in prostate cancer.

Authors:  D G Bostwick; J Qian; E Bergstralh; P Dundore; J Dugan; R P Myers; J E Oesterling
Journal:  J Urol       Date:  1996-04       Impact factor: 7.450

9.  Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies.

Authors:  H Huland; P Hammerer; R P Henke; E Huland
Journal:  J Urol       Date:  1996-04       Impact factor: 7.450

10.  Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue.

Authors:  F Brimo; R T Vollmer; J Corcos; K Kotar; L R Bégin; P A Humphrey; T A Bismar
Journal:  Histopathology       Date:  2008-08       Impact factor: 5.087

View more
  8 in total

1.  Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP).

Authors:  Solene-Florence Kammerer-Jacquet; Eva Compérat; Lars Egevad; Ondra Hes; Jon Oxley; Murali Varma; Glen Kristiansen; Daniel M Berney
Journal:  Virchows Arch       Date:  2018-01-11       Impact factor: 4.064

2.  Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study.

Authors:  D M Moreira; J C Nickel; G L Andriole; R Castro-Santamaria; S J Freedland
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-01-19       Impact factor: 5.554

3.  The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens.

Authors:  D M Moreira; D M de O Freitas; J C Nickel; G L Andriole; R Castro-Santamaria; S J Freedland
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-06-06       Impact factor: 5.554

4.  Gleason underestimation is predicted by prostate biopsy core length.

Authors:  Leonardo O Reis; Brunno C F Sanches; Gustavo Borges de Mendonça; Daniel M Silva; Tiago Aguiar; Ocivaldo P Menezes; Athanase Billis
Journal:  World J Urol       Date:  2014-08-02       Impact factor: 4.226

5.  Applying precision medicine to the active surveillance of prostate cancer.

Authors:  Chad A Reichard; Andrew J Stephenson; Eric A Klein
Journal:  Cancer       Date:  2015-07-06       Impact factor: 6.860

Review 6.  Prevalence of incidental prostate cancer: A systematic review of autopsy studies.

Authors:  Katy J L Bell; Chris Del Mar; Gordon Wright; James Dickinson; Paul Glasziou
Journal:  Int J Cancer       Date:  2015-04-21       Impact factor: 7.396

7.  Predictive criteria of insignificant prostate cancer: what is the correspondence of linear extent to percentage of cancer in a single core?

Authors:  Athanase Billis; Maisa M Q Quintal; Leandro L L Freitas; Larissa B E Costa; Ubirajara Ferreira
Journal:  Int Braz J Urol       Date:  2015 Mar-Apr       Impact factor: 1.541

Review 8.  Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review.

Authors:  A Marije Hoogland; Charlotte F Kweldam; Geert J L H van Leenders
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.